Jubilant HollisterStier has grabbed a $146.6 million contract from the US government, continuing to ride the industrial expansion wave created by the COVID-19 business boom. The contract, which was signed with numerous agencies of the Department of Health and Human Services, will allow the CDMO in Spokane, Washington, to increase its injectable capacity to satisfy current needs and plan for future pandemics.
The contract, which is funded by the American Rescue Plan, allows Jubilant a total of $193 million to invest in its production facilities, according to the company. It plans to finish the contract-funded expansion by 2025.
In a statement, President Amit Arora said, Jubilant’s growth will address large pharmaceutical and biotech businesses for parenteral medicines, as well as include a versatile manufacturing platform capable of producing many types of vaccines. This commitment will safeguard the capacity to quickly create high-quality vaccines and treatments for the consumer, as well as better prepare everyone for any future challenges to the country.
Jubilant announced plans for a $92 million expansion of the facility in June 2021 that included high-speed injectable fill lines with isolator technology that would increase throughput by 50% to 400 vials per minute.
Earlier that year, the business said it was producing COVID-19 treatments including Gilead’s remdesivir and Eli Lilly’s bamlanivimab all around clock, seven days a week, to fulfil demand. In March 2021, the business also signed a fill-finish arrangement with Novavax for its COVID-19 vaccine.
